FBXL19-AS1: A Potential Drug Target and Biomarker (G283932)

Target Name: FBXL19-AS1

NCBI ID: G283932

FBXL19-AS1

Other Name(s): NCRNA00095 | FBXL19 antisense RNA 1

FBXL19-AS1: A Potential Drug Target and Biomarker

FBXL19-AS1, also known as NCRNA00095, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. FBXL19-AS1 is a key regulator of the myeloid-specific gene expression, and its dysfunction has been implicated in the development and progression of various leukemias, as well as other diseases.

The function of FBXL19-AS1 is to regulate the expression of genes in the myeloid lineage, specifically those that encode for proteins involved in the development and maintenance of myeloid cells. FBXL19-AS1 is expressed in almost all human tissues and has been shown to play a critical role in the development and maintenance of myeloid cells, including the formation of leukemia cells.

One of the key functions of FBXL19-AS1 is its ability to induce the expression of genes involved in the development and maintenance of myeloid cells. For example, studies have shown that FBXL19-AS1 can induce the expression of genes involved in the production of DNA damage repair proteins, which are important for the maintenance of myeloid cells. Additionally, FBXL19-AS1 has been shown to induce the expression of genes involved in the production of signaling proteins, which are important for the regulation of cellular processes that promote cell growth and proliferation.

FBXL19-AS1 has also been shown to play a key role in the regulation of the cellular response to chemotherapy. Studies have shown that FBXL19-AS1 can inhibit the effects of chemotherapy drugs, particularly those that are designed to kill myeloid cells. This suggests that FBXL19-AS1 may be a potential drug target for cancer treatment, particularly for those who are characterized by the development of myeloid leukemias.

In addition to its role in the regulation of myeloid cells, FBXL19-AS1 has also been shown to play a critical role in the development and progression of various diseases, including cancer. For example, studies have shown that FBXL19-AS1 is involved in the regulation of the development and progression of various types of leukemias, including acute myeloid leukemia and chronic myeloid leukemia. Additionally, FBXL19-AS1 has been shown to be involved in the regulation of the development and progression of other diseases, including autoimmune diseases and neurodegenerative diseases.

Despite its potential as a drug target and biomarker, FBXL19-AS1 is still a relatively unstudied molecule. There are currently few research studies focused on the characterization of FBXL19-AS1 and its potential as a drug target or biomarker. However, as more research is conducted on this molecule, it is likely that its potential as a drug target and biomarker will become clearer.

In conclusion, FBXL19-AS1 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its function as a regulator of myeloid cell development and the regulation of cellular processes that promote cell growth and proliferation makes it a promising target for cancer treatment. Further research is needed to fully understand the potential of FBXL19-AS1 as a drug target and biomarker.

Protein Name: FBXL19 Antisense RNA 1

The "FBXL19-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBXL19-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets